Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797935 | 1.00 | TYMP (0.58) | TYMPLMNAADORA1P2RY12ADORA2A | |
| SCHEMBL21245356 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL21284194 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL26906442 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL8359090 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL8359092 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL32679036 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL22034220 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL32679034 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL25874925 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| EP-3692048-A2 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2020-08-12 | — | — | EP | disclosed |
| CN-111263767-A | Cyclic dinucleotides as stimulators of interferon gene modulators | 北京轩义医药科技有限公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-3507367-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro BioTech, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2019043634-A2 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-03-07 | — | — | WO | disclosed |
| EP-3368072-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT SIGNALLING | Aduro BioTech, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2018009466-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2018-01-11 | — | — | WO | disclosed |
| WO-2017075477-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075477-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | TYMP 735/4885LMNA 474/4885ADORA1 336/4885 |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | TYMP 2232/4885LMNA 2274/4885ADORA1 296/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | TYMP 1196/4885LMNA 4707/4885ADORA1 884/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | TYMP 1196/4885LMNA 4707/4885ADORA1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.